Employer intelligence

Self-insured employers (platform)

Public direct contracting intelligence involving Self-insured employers (platform). This page aggregates tracked provider relationships, contract structures, reported economics, and primary sources from the DirectContract database.

Tracked contracts

—

Covered lives represented

Active or expanded

—

Highest reported savings

Tracked arrangements

Eli Lilly (Zepbound / tirzepatide) ↔ Self-insured employers (platform)

United States · 2026-03

Eli Lilly launched a direct-to-employer platform for tirzepatide (Zepbound) in March 2026, enabling self-insured employers to access GLP-1 obesity treatment at transparent prices without PBM intermediaries. The model cuts spread pricing and allows employers to offer the drug as a defined benefit at a predictable cost.

Model: Transparent Pricing

Status: active

Lives: Not disclosed

Savings: Reduced GLP-1 costs by bypassing PBM spread pricing

Primary source ↗

Waltz Health ↔ Self-insured employers (platform)

United States · 2025-11

Waltz Health launched a direct-to-employer access model for GLP-1 obesity management medications in November 2025. The platform allows self-insured employers to offer tirzepatide and semaglutide at transparent, contracted prices without traditional PBM markup.

Model: Transparent Pricing

Status: active

Lives: Not disclosed

Savings: Lower net cost on obesity management drugs vs. traditional PBM

Primary source ↗

Henry Ford Health ↔ Self-insured employers (platform)

Michigan · 2025-01

Henry Ford Health launched a direct contracting platform offering self-insured employers structured access to its integrated Michigan health system. The 2025 offering expands beyond the original 2018 GM arrangement into a multi-employer platform model.

Model: Transparent Pricing

Status: active

Lives: Not disclosed

Savings: Not disclosed

Primary source ↗

Explore all contracts Get the Friday briefing